MediSetter Interview: Insight on Opportunities in Asia's Healthcare Industry
Introduction to MedisetterI had the pleasure of interviewing Anirban Lahiri of Medisetter to discuss some of the opportunities present in Asia's...
4k Views
SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
* In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
249 Views
SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
253 Views
SillaJen IPO Part 1 - Schedule, Financials & Valuation
SillaJen Biotherapeutics (established in 2006) submitted the IPO report. The company develops potent multi-functional immunotherapeutics for...
352 Views
Hanmi Pharmaceutical: This Korean Pharma Giant's Stock Could Rebound More than 50%.
Hanmi Pharm Co Ltd (128940 KS) stock has fallen from recent highs after Boehringer pulled out of an oncology deal and short-sellers piled on the...
627 Views